This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection
by Zacks Equity Research
Ceribell wins FDA Breakthrough status for its AI-driven EEG solution to detect and monitor LVO strokes in hospitals, boosting credibility and growth outlook.
BSXPositive Net Change ISRGPositive Net Change MEDPPositive Net Change CBLLPositive Net Change
medical medical-devices
ANIP Up 21% in 6 Months: Is It Worth Investing in the Stock Now?
by Sundeep Ganoria
ANI Pharmaceuticals' shares are up 21% in six months as strong 2025 results, repeated earnings beats and higher guidance highlight momentum in rare diseases.
TEVAPositive Net Change ANIPNegative Net Change AMRXPositive Net Change
biotechs medical
OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device
by Zacks Equity Research
OSUR files FDA applications seeking approval for two at-home STI tests, advancing decentralized diagnostics; shares gain 3.8% as it targets long-term growth.
BSXPositive Net Change OSURPositive Net Change ATRCPositive Net Change SMTIPositive Net Change
medical medical-devices
MRNA Stock Jumps on Global Submissions Seeking Nod for Flu Vaccine
by Zacks Equity Research
Moderna jumps after filings seeking approval for its mRNA-1010 flu vaccine across major markets, with plans to launch the shot for older adults next year.
SNYPositive Net Change GSKPositive Net Change MRNAPositive Net Change
biotechs medical messenger-rna vaccines
Centene Jumps 16.3% in 3 Months: A Comeback or Calm Before the Storm?
by Kaibalya Pravo Dey
CNC shares jump 16.3% in three months, but high medical costs and thin margins keep the recovery debate alive.
UNHPositive Net Change CNCPositive Net Change ELVPositive Net Change
insurance medical
Tilray Brands Readies for Q2 Earnings: Here's What You Should Know
by Zacks Equity Research
TLRY's faces margin pressure in cannabis and beverages, but management sees a beverage turnaround and wellness strength cushioning quarterly results.
STZPositive Net Change MNSTPositive Net Change CELHPositive Net Change TLRYNegative Net Change
medical
Cigna Shares on the Couch: Time to Stay Strong or Walk Away Now?
by Zacks Equity Research
CI looks worth holding as Evernorth growth, expanding pharmacy services, cheap valuation and shareholder returns support its long-term outlook.
CIPositive Net Change ENSGPositive Net Change CDNANegative Net Change EHCPositive Net Change
insurance medical
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma
by Zacks Equity Research
Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.
BMYPositive Net Change INCYPositive Net Change ANIPNegative Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Top Robotics Stocks That Could Drive Impressive Returns in 2026
by Vasundhara Sawalka
Robotics is poised for steady growth in 2026. Consider PATH, NVDA, CDNS and ISRG for potential market dominance across sectors.
ISRGPositive Net Change NVDANegative Net Change HYMLFNo Net Change CDNSPositive Net Change PATHPositive Net Change
artificial-intelligence medical robotics tech-stocks
Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026?
by Ahan Chakraborty
Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug a chance to revive 2026 momentum.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Hologic's Breast Health Unit Stays In Focus in 2026: What Lies Ahead?
by Moumi Mondal
HOLX's Breast Health unit is back in focus as a proposed Blackstone-TPG deal adds a $76 cash offer and CVR to 2026-27 revenue goals.
DGXPositive Net Change HOLXPositive Net Change GEHCPositive Net Change
medical medical-devices
Should Labcorp Stock Stay in Your Portfolio Right Now?
by Zacks Equity Research
LH's growth bets in specialty testing and acquisitions support its outlook, but macro pressures and currency headwinds remain key risks.
LHPositive Net Change DGXPositive Net Change PAHCPositive Net Change BTSGPositive Net Change
medical medical-devices
Three Genomics Stocks Worth Tracking This Year
by Ekta Bagri
Genomics advances are reshaping drug discovery, with Pacific Biosciences of California emerging as a key player in next-gen sequencing.
ILMNPositive Net Change BEAMPositive Net Change PACBPositive Net Change WVEPositive Net Change CRSPPositive Net Change SANAPositive Net Change
biotechnology biotechs cell-therapy gene-therapy genetics genomics medical pharmaceuticals thematic
OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth
by Zacks Equity Research
OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.
BSXPositive Net Change ISRGPositive Net Change OPKPositive Net Change MEDPPositive Net Change
medical medical-devices
New Strong Buy Stocks for January 6th
by Zacks Equity Research
ILPT, NMTC, RIGL, RIO and BHP have been added to the Zacks Rank #1 (Strong Buy) List on January 6th, 2026.
BHPPositive Net Change RIOPositive Net Change RIGLPositive Net Change ILPTPositive Net Change NMTCPositive Net Change
construction medical reit
The Zacks Analyst Blog Chevron, Lockheed, Northrop, CrowdStrike and Palo Alto
by Zacks Equity Research
Lockheed Martin highlights how U.S. action in Venezuela may shift market dynamics, with defense, tech and healthcare stocks emerging as key beneficiaries.
LMTPositive Net Change NOCNegative Net Change CVXNegative Net Change PANWPositive Net Change CRWDPositive Net Change
medical
The Zacks Analyst Blog Eli Lilly, Medtronic, Intuitive Surgical, Regeneron Pharmaceuticals and Johnson & Johnson
by Zacks Equity Research
Eli Lilly highlights how AI is transforming healthcare, from drug discovery to diagnostics, turning defensive medical stocks into growth plays for 2026.
REGNPositive Net Change JNJPositive Net Change LLYPositive Net Change MDTPositive Net Change ISRGPositive Net Change
medical
Zacks Investment Ideas feature highlights Pagaya, Eli Lilly and Weatherford
by Zacks Equity Research
Pagaya, Eli Lilly and Weatherford have been highlighted in this Investment Ideas article.
LLYPositive Net Change WFRDPositive Net Change PGYNegative Net Change
medical
Top Stock Reports for Meta, Bank of America & Procter & Gamble
by Mark Vickery
Meta Platforms leads today's Zacks Research Daily as analysts highlight strong user growth, heavier AI investment and lingering concerns around monetization.
BACPositive Net Change PGNegative Net Change JBLPositive Net Change NVRNegative Net Change ESPNegative Net Change CVNAPositive Net Change METAPositive Net Change NRXSPositive Net Change
aerospace computers consumer-staples finance medical
Venezuela Shock 2026: Defense, Tech, Healthcare Stocks Set to Benefit
by Urmimala Biswas
U.S. capture of Venezuela leadership shakes markets, but defense, tech and healthcare look set to gain. Meanwhile, oil impact stays muted for Chevron.
LMTPositive Net Change NOCNegative Net Change CVXNegative Net Change PANWPositive Net Change CRWDPositive Net Change
aerospace alt-energy computers energy medical semiconductor tech-stocks
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026?
by Zacks Equity Research
KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.
REGNPositive Net Change SNYPositive Net Change GILDPositive Net Change KYMRPositive Net Change
biotechnology biotechs medical pharmaceuticals
McKesson Builds Earnings Momentum on Specialty and Automation
by Zacks Equity Research
McKesson posts a strong fiscal second quarter, lifts full-year EPS outlook, and shows how specialty growth and automation are reshaping its earnings power.
CAHPositive Net Change MCKPositive Net Change CVSPositive Net Change CORPositive Net Change
medical medical-devices
Here's Why You Should Retain Masimo Stock in Your Portfolio Now
by Zacks Equity Research
MASI's strong Q3 2025 results, FDA clearance and partnerships fuel growth hopes, but SET dependence and reimbursement risks linger.
MASIPositive Net Change VCYTPositive Net Change TCMDPositive Net Change AORTPositive Net Change
medical medical-devices
Hims & Hers Expands Data-Driven, AI-Enabled Care and Personalization
by Debanjana Dey
HIMS deepens its AI and data strategy with personalized care tools, biomarker tracking, and smarter treatment matching.
HIMSPositive Net Change DOCSNo Net Change TEMPositive Net Change
medical medical-devices
3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY)
by Ethan Feller
Eli Lilly, Pagaya Technologies Ltd. and Weatherford International stocks all boast numerous bullish tailwinds heading into this new year.
LLYPositive Net Change WFRDPositive Net Change PGYNegative Net Change
energy fin-tech medical